SCHEMBL17048299

SCHEMBL17048299

CCc1ccc(N)cc1C1CCN(C(=O)O)CC1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 1/20 0.36
HTR1B P28222 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SLC9A1 P19634 3/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
RBP4 P02753 2/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
STAT1 P42224 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TRPC6 Q9Y210 3/20 0.35
SIGMAR1 Q99720 1/20 0.34
QDPR P09417 1/20 0.34
CCR2 P41597 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17395599 0.89 SLC9A1 (0.38) HTR1DHTR1BMEN1KMT2ASLC9A1
SCHEMBL3812754 0.83 DRD2 (0.41) HTR1DHTR1BMEN1KMT2ASLC9A1
SCHEMBL17054287 0.82 MAPT (0.49) CYP3A4CYP2C9CYP2C19NPC1MAPT
SCHEMBL16825003 0.81 RBP4 (0.35) HTR1DHTR1BMEN1KMT2ASLC9A1
SCHEMBL3816206 0.80 RBP4 (0.39) HTR1DHTR1BMEN1KMT2ASLC9A1
SCHEMBL15524740 0.80 OPRL1 (0.41) HTR1DHTR1BMEN1KMT2ASLC9A1
SCHEMBL4771915 0.80 MEN1 (0.52) MEN1KMT2AMAPTTRPC6QDPR
SCHEMBL17048220 0.78 NPC1 (0.41) RBP4NPC1MAPTSTAT1RAB9A
SCHEMBL24172412 0.77 BACE1 (0.40) HTR1DHTR1BNPC1MAPTRAB9A
SCHEMBL31140149 0.77 PARP10 (0.41) SLC9A1CYP3A4CYP2C9CYP2C19RBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3110815-B1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEV INC (CN) 2020-02-19 EP disclosed
US-9783539-B2 Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2017-10-10 US disclosed
US-20170066761-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2017-03-09 US disclosed
EP-3110815-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS Jiangsu Ascentage Biomed Development Inc. (CN) 2017-01-04 EP disclosed
WO-2015127629-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. (CN) 2015-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066761-A1 INDOLOQUINOLONE COMPOUNDS AS ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS ALK, BCL6, BCL6B HTR1D 3634/4885HTR1B 2668/4885MEN1 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.